NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, version 2.2019: Featured updates to the NCCN Guidelines Journal Article


Authors: Wierda, W. G.; Byrd, J. C.; Abramson, J. S.; Bilgrami, S. F.; Bociek, G.; Brander, D.; Brown, J.; Chanan-Khan, A. A.; Chavez, J. C.; Coutre, S. E.; Davis, R. S.; Fletcher, C. D.; Hill, B.; Kahl, B. S.; Kamdar, M.; Kaplan, L. D.; Khan, N.; Kipps, T. J.; Ma, S.; Malek, S.; Mato, A.; Mosse, C.; Neppalli, V. T.; Shadman, M.; Siddiqi, T.; Stephens, D.; Wagner, N.; Dwyer, M. A.; Sundar, H.
Article Title: NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, version 2.2019: Featured updates to the NCCN Guidelines
Abstract: Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter's transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation. Copyright © 2019 by the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 17
Issue: 1
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2019-01-01
Start Page: 12
End Page: 20
Language: English
DOI: 10.6004/jnccn.2019.0002
PUBMED: 30659125
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 February 2019 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Anthony R Mato
    28 Mato